HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

dironyl (terguride)

pronounced antifertility agent in rats; lactation suppressor in other species; serotonin antagonist; RN given refers to parent cpd; structure

Also Known As:

terguride; N-(D-6-methyl-8-isoergolin-1-yl)-N',N'-diethylurea; VUFB 6638; dironyl maleate (1:1); transdihydrolisuride; urea, N,N-diethyl-N'-((8 alpha)-6-methylergolin-8-yl)-, (Z)-2-butenedioate (1:1)

Networked: 60 relevant articles (9 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- Alkaloids: 1065
  - Ergot Alkaloids: 156
    - Ergolines: 88
      - Lisuride: 222
        dironyl: 60
- Heterocyclic Compounds with 4 or More Rings
  - Ergolines: 88
    - Lisuride: 222
      - dironyl: 60

Experts

1.	Schermuly, Ralph Theo: 2 articles (01/2015 - 11/2010)
2.	Seeger, Werner: 2 articles (01/2015 - 11/2010)
3.	Reiter, Rudolf: 2 articles (11/2010 - 01/2010)
4.	Waldum, Helge L: 2 articles (11/2008 - 10/2007)
5.	Gustafsson, Björn I: 2 articles (11/2008 - 10/2007)
6.	Bednarski, Marek: 1 article (04/2015)
7.	Nowak, Gabriel: 1 article (04/2015)
8.	Sapa, Jacek: 1 article (04/2015)
9.	Zajdel, Paweł: 1 article (04/2015)
10.	Schymura, Yves: 1 article (01/2015)

Related Diseases

1.	Dyskinesias (Dyskinesia) 09/01/1993 - "Terguride for dyskinesias." 08/01/1990 - "Terguride, a partial DA-agonist with both dopaminergic and antidopaminergic properties, was tested in 11 PD patients in the "decompensated" phase of the disease, characterized by the presence of dyskinesias and motor fluctuations. " 04/01/1995 - "Terguride also improved the parkinsonism but did not induce the hyperactivity and dyskinesias. " 08/01/1990 - "Combined treatment of these patients with 1 mg/day of terguride and stabilized doses of levodopa reduced the severity and frequency of dyskinesias and motor fluctuations along with a slight but significant improvement of parkinsonian clinical picture. " 04/01/1995 - "On the other hand, combination treatment of terguride with SKF 82958 also augmented the antiparkinsonian effects but did not induce any hyperactivity and dyskinesias. "
2.	Parkinson Disease (Parkinson's Disease) 05/01/1993 - "Terguride thus exhibits both antiparkinsonian and antihyperactivity effects in a monkey model of Parkinson's disease, suggesting that terguride might be beneficial for treating motor dysfunction and dopaminergic psychosis in advanced Parkinson's disease." 05/01/1995 - "Terguride in stable Parkinson's disease." 03/03/1992 - "It is concluded that terguride has anti-akinetic efficacy in this primate model of Parkinson's disease. " 10/01/1991 - "Antagonist effect of terguride in Parkinson's disease." 08/01/1990 - "Terguride in the treatment of Parkinson disease: preliminary experience."
3.	Fibrosis (Cirrhosis) 11/01/2010 - "Blockade of 5-HTR(2A/B) signalling by terguride reversed lung fibrosis and is thus a promising therapeutic approach for IPF." 01/01/2015 - "Chronic treatment with Terguride or SB204741 reduced right ventricular fibrosis and showed improved heart function in mice after PAB. " 11/01/2010 - "To assess the effects of 5HTR(2A/B) inhibition on fibrogenesis in vivo, mice were subjected to bleomycin-induced lung fibrosis and treated with the 5-HTR(2A/B) antagonist terguride (or vehicle) in a therapeutic approach (days 14-28 after bleomycin). " 11/01/2008 - "In the current study, the carbon tetrachloride (CCL(4)) hepatic fibrosis rat model was used in combination with daily administration of terguride to evaluate potential preventive effects of a 5-HT(2) receptor antagonist upon liver fibrosis. " 11/01/2008 - "Terguride, recognized as a partial dopamine agonist, also has potent 5-HT(2) receptor antagonist qualities and has been shown to prevent serotonin-induced organ changes and fibrosis in rats. "
4.	Pain (Aches) 01/01/2010 - "FIQ scores improved significantly (per-protocol analysis), and pain intensity, the TPS score, and the HDS score showed a trend toward improvement in the terguride group as compared with the placebo group. " 01/01/2010 - "Terguride treatment did not improve pain, the FIQ score, the TPS, or the HDS score in the total study population. " 01/01/2010 - "No significant differences in the change in pain intensity, FIQ score, TPS, or HDS score between baseline and 12 weeks were observed in the terguride group as compared with the placebo group. "
5.	Parkinsonian Disorders (Parkinsonism) 05/01/1993 - "Terguride alone ameliorated the parkinsonism without inducing any sign of excitability, irritability, or aggressiveness (hyperactivity). " 01/01/1988 - "Terguride in parkinsonism. " 01/01/1987 - "Transdihydrolisuride in parkinsonism." 04/01/1995 - "Terguride also improved the parkinsonism but did not induce the hyperactivity and dyskinesias. " 06/01/1992 - "Terguride produced a dose-dependent decrease in levodopa-induced dyskinesias (up to 53%) in seven patients without concomitant worsening of parkinsonism, and had no significant antiparkinsonian effect when administered alone. "

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	Lisuride
3.	Bromocriptine (Parlodel)
4.	Monocrotaline
5.	Urea (Carbamide)
6.	Ergolines
7.	Antiparkinson Agents (Antiparkinsonian Agents)
8.	ergocornine
9.	ergocryptine
10.	N- (1- methyl- 5- indolyl)- N'- (3- methyl- 5- isothiazolyl)urea

Related Therapies and Procedures

1.	Oral Administration
2.	Drug Therapy (Chemotherapy)